Abstract
【Purpose】 The phase III CheckMate 025 trial showed that nivolumab improved clinical benefit in advanced renal cell carcinoma. Herein, we report the efficacy and safety of nivolumab for metastatic renal cell carcinoma (mRCC) patients in a Japanese single institution.
【Material and Methods】 Twenty-eight mRCC patients who had failed prior molecular targeted therapy (MTT) were treated with nivolumab between December 2016 and December 2017. Our cohort included heterogeneous cases with non-clear cell carcinoma, three or more prior lines of MTT, and a higher proportion in the poor risk group.
【Results】 Median overall survival and progression-free survival were 11.7 and 6.1 months, respectively. The objective response rate and clinical benefit rate were 8.3 and 75.0%, respectively; one case achieved complete response. Any-grade and severe nivolumab-related adverse events in our cohort accounted for 50.0 and 3.6%, respectively.
【Conclusion】 The current results showed the usefulness of nivolumab treatment for mRCC patients, regardless of the small cohort with heterogeneous characteristics studied.
